Drug Database · Clinicians

Teicoplanin

Brands (11) Camillanin, Teclotan, Teicopix…Show all

Antibacterial (glycopeptide antibacterial); Antibacterial (glucopeptide) PH FDA category

From day 4: CrCl 30–80 ½, <30 ⅓ doseRx · Prescription drug15 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Hypersensitivity to teicoplanin
renalcarematters.com, reviewed

Dosing: Adult

  • Complicated skin and soft tissue infection, pneumonia, complicated urinary tract infection: Loading 6 mg/kg IV or IM every 12 hours for 3 doses, then 6 mg/kg once daily
  • Bone and joint infection: Loading 12 mg/kg IV every 12 hours for 3 to 5 doses, then 12 mg/kg once daily
  • Infective endocarditis: Loading 12 mg/kg IV every 12 hours for 3 to 5 doses, then 12 mg/kg once daily; usually at least 21 days
  • Clostridioides difficile diarrhea (oral): 100 to 200 mg orally twice daily for 7 to 14 days
renalcarematters.com, reviewed

Dosing: Altered kidney function

Teicoplanin is a glycopeptide excreted about 80% unchanged in urine, with a very long terminal half-life (100 to 170 hours). The European label gives the full loading dose, then from day 4 halves the maintenance dose at creatinine clearance (CrCl) 30–80 mL/min and gives one-third at CrCl below 30 mL/min and on hemodialysis, guided by trough levels. Hemodialysis does not remove it. It has no US FDA label.

Kidney function measure: European summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min); thresholds 80 and 30.

Show full dosing details
CrCl ≥60 mL/min
CrCl >80: usual loading and maintenance doses (e.g., 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg once daily; 12 mg/kg for bone, joint and endocarditis). CrCl 60–80: no change until day 4, then half the maintenance dose (full dose every 2 days or half dose daily) (SmPC).
CrCl 30–59 mL/min
Usual loading doses; from day 4, half the maintenance dose: the full dose every 2 days or half the dose once daily (SmPC: CrCl 30–80). Keep trough at least 15 mg/L (FPIA) or 10 mg/L (HPLC).
CrCl 15–29 mL/min
Usual loading doses; from day 4, one-third of the maintenance dose: the full dose every 3 days or one-third once daily (SmPC: CrCl <30). Guide by trough levels.
CrCl <15 mL/min (not on dialysis)
Usual loading doses; from day 4, one-third of the maintenance dose (full dose every 3 days or one-third daily) (SmPC). Guide by trough levels.
Hemodialysis (intermittent)
As for CrCl <30: usual loading, then one-third of the maintenance dose from day 4 (every third day or one-third daily). Not removed by hemodialysis; no supplement needed (SmPC).
Peritoneal dialysis
CAPD peritonitis: single intravenous loading dose of 6 mg/kg, then 20 mg/L in the dialysate: week 1 in every bag; week 2 in alternate bags; week 3 in the overnight bag only (SmPC). Removed only slowly by peritoneal dialysis.
CRRT
No CRRT dosing in the SmPC. Use trough-guided dosing; specialist input.
  • Dialyzable? No: not removed by hemodialysis; removed only slowly by peritoneal dialysis (SmPC 4.2, 4.9).
  • Monitoring Trough concentrations at steady state after loading and at least weekly during maintenance (trough targets by FPIA: at least 15 mg/L for complicated skin and soft-tissue infection, pneumonia and complicated urinary tract infection; above 20 mg/L for bone and joint infection; 30–40 mg/L after loading and above 30 mg/L during maintenance for endocarditis). In kidney impairment, set the day-4 reduction by trough rather than by CrCl alone. Kidney function closely in CKD, after high loading doses and with nephrotoxic drugs. Hearing tests with ototoxic or nephrotoxic co-medication. Blood counts periodically (SmPC 4.4).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Normal kidney function: usual weight-based doses (SmPC).
eGFR 30–59
No pediatric-specific kidney adjustment in the SmPC; adult principle (reduce maintenance from day 4, trough-guided) is a reasonable guide. Specialist input.
eGFR 15–29
No pediatric-specific kidney adjustment in the SmPC; adult principle (reduce maintenance from day 4, trough-guided) is a reasonable guide. Specialist input.
eGFR <15 (not on dialysis)
No pediatric-specific kidney adjustment in the SmPC; adult principle (reduce maintenance from day 4, trough-guided) is a reasonable guide. Specialist input.
Hemodialysis (intermittent)
No pediatric data; trough-guided specialist dosing.
Peritoneal dialysis
No pediatric data; trough-guided specialist dosing.
CRRT
No pediatric data; trough-guided specialist dosing.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: MPA (Sweden) product information (December 11, 2025). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
All ages, from neonates (SmPC).
Usual dose
Neonates and infants up to 2 months: 16 mg/kg intravenously on day 1, then 8 mg/kg once daily (infusion only). 2 months to 12 years: 10 mg/kg every 12 hours for 3 doses, then 6 to 10 mg/kg once daily. Over 12 years: adult doses (SmPC).

Pediatric half-life about 40 hours in neonates and 58 hours at a mean age of 8 years.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Lyophilized powder for injection: 200 mg, 400 mg
  • Powder for injection: 200 mg, 400 mg
  • Lyophilized powder for solution for injection: 200 mg, 400 mg
  • Lyophilized powder for solution for injection/infusion: 200 mg, 400 mg
  • Powder for injection ): 200 mg
  • Powder for solution for injection: 400 mg

Registered products in the Philippines

15 products registered with the Food and Drug Administration (FDA) Philippines list Teicoplanin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products15
Philippine FDA-registered products for Teicoplanin
Package insert
Brutio 200Teicoplanin
200 mg Lyophilized Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Yellow Flip-Off Seal (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-14945
May 23, 2031
Brutio 400Teicoplanin
400 mg Lyophilized Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Orange Flip-Off Seal (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-14944
May 23, 2031
CamillaninTeicoplanin
200 mg Lyophilized Powder for Solution for Injection (IM/IV)10mL-Capacity Type I Clear Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Purple Flip-Off Cap x 1's (Box of 1's)
Rx
Sichuan Huiyu Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-17581
Feb 4, 2032
CamillaninTeicoplanin
400 mg Lyophilized Powder for Solution for Injection (IM/IV)20mL-Capacity Type I Clear Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Orange Flip-Off Cap x 1's (Box of 1's)
Rx
Sichuan Huiyu Pharmaceutical Co. Ltd.China
AMB HK Enterprises, Inc.
DRP-17582
Feb 4, 2032
ImtecTeicoplanin
400 mg Lyophilized Powder for Injection (I.M./I.V.)In a box containing: 10 mL USP type I flint tubular glass vial with bromobutyl rubber slotted and red Alu flip-off seal + 5 mL USP type I ampoule (Sterilized Water for Injection as diluent) Box of 1's
Rx
Gufic Biosciences Ltd.India
Philcare Pharma Inc.Importer: SRS Life Sciences Inc.
DR-XY45058
Feb 23, 2031
PlanicidTeicoplanin
400mg Lyophilized Powder for Injection (IM/IV)20 mL-capacity Type I clear glass vial with aluminum flip off cap and bromobutyl rubber stopper (Box of 1's)
Rx
Centurion İlaç Sanayi ve Ticaret A.Ş. Ankara ŞubesiTurkey
Stangen Pharmaceuticals Philippines Inc.
DRP-12851
Oct 14, 2027
TeclotanTeicoplanin
200 mg Powder for Injection (IM/IV)Type II glass vial, with grey bromobutyl rubber stopper, aluminum seal and yellow PP flip-off cap (Box)
Rx
Venus Remedies LimitedIndia
Despina Pharma Inc.
DRP-16726
Jul 1, 2030
TeclotanTeicoplanin
400 mg Powder for Injection (IM/IV)Type II glass vial, with grey bromobutyl rubber stopper, aluminum seal and blue PP flip-off cap (Box of 1's)
Rx
Venus Remedies LimitedIndia
Despina Pharma Inc.
DRP-16725
Jul 1, 2030
Teiconova-400Teicoplanin
400 mg Powder for Solution for Injection (IM/IV)20 mL-capacity USP Type I clear colorless glass vial + 3 mL USP Type I colorless glass ampoule (Sterile water for injection as solvent) [Box of 1's]
Rx
Dongkook Pharmaceutical Co., Ltd.Korea
Medinova Pharmaceutical Inc.
DRP-15034
Mar 21, 2029
TeicopixTeicoplanin
200 mg Lyophilized Powder for solution for Injection/InfusionPh. Eur. Type I clear and colorless glass vial with dark gray bromobutyl rubber stopper and aluminum seal with green polypropylene flip-off cap + 3 mL Water for Injection (as solvent) in Ph. Eur. Type I clear and colorless glass ampoule (Box of 1's and 5's)
Rx
Lek Pharmaceuticals d.d.Slovenia
Importer: Sandoz Philippines Corporation
DRP-13389
Feb 10, 2028
TeicopixTeicoplanin
400 mg Lyophilized Powder for solution for Injection/InfusionPh. Eur. Type I clear and colorless glass vial with dark. gray bromobutyl rubber stopper and aluminum seal with blue polypropylene flip-off cap + 3 mL Water for Injection (as solvent) in Ph. Eur. Type I clear and colorless glass ampoule (Box of 1's and 5's)
Rx
Lek Pharmaceuticals d.d.Slovenia
Importer: Sandoz Philippines Corporation
DRP-13390
Feb 10, 2028
Teicotan 200Teicoplanin
200 mg Lyophilized Powder for Injection (IM/IV)USP Type I flint glass tubular vial (as active) + USP Type I clear transparent ampoule x 5 mL (as diluent) in a plastic tray
Rx
Gufic Biosciences LimitedIndia
SRS Life Sciences Inc.
DR-XY43894
Nov 13, 2029
TicorayTeicoplanin
200mg Powder For Injection (IV/IM))10 mL USP Type I glass vial with dark grey bromobutyl stopper and aluminum flip-off seal (Box of 1’s)
Rx
Mylan Laboratories Limited (Sterile Products Division)India
Mylan Philippines Inc
DR-XY48156
Jul 1, 2027
TicorayTeicoplanin
400mg Powder For Injection (IV/IM)20 mL USP type I glass vial with dark grey bromobutyl stopper and aluminum flip-off seal (Box of 1’s)
Rx
Mylan Laboratories Limited (Sterile Products Division)India
Mylan Philippines Inc.
DR-XY48161
Jul 4, 2027
VellaninTeicoplanin
400 mg Powder for Injection (I.M./I.V.)6 mL-capacity Type I clear and colorless glass vial with gray Type I rubber stopper and aluminum seal with orange PP flip-off cap (Box of 1's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare, Inc.
DR-XY47721
Feb 11, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Aminoglycosides, colistin, amphotericin B, cyclosporine, cisplatin, loop diuretics (furosemide, ethacrynic acid)Adjust or monitorAdditive nephrotoxicity or ototoxicity.Use with care; monitor kidney function and hearing.
Aminoglycosides (same syringe or bag)MinorPhysically incompatible for injection.Do not mix (compatible in CAPD fluid).

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Rash, erythema, pruritus
  • Pain, fever

Serious

  • Nephrotoxicity and acute kidney failure (about 2% on standard loading; 11% to 27% with high loading regimens)
  • Ototoxicity: deafness, tinnitus, vestibular disorder
  • Agranulocytosis, neutropenia, thrombocytopenia
  • Anaphylaxis, red man syndrome
  • Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis
  • Seizures
renalcarematters.com, reviewed

Monitoring parameters

  • Trough concentrations at steady state after loading and at least weekly during maintenance (trough targets by FPIA: at least 15 mg/L for complicated skin and soft-tissue infection, pneumonia and complicated urinary tract infection; above 20 mg/L for bone and joint infection; 30–40 mg/L after loading and above 30 mg/L during maintenance for endocarditis). In kidney impairment, set the day-4 reduction by trough rather than by CrCl alone. Kidney function closely in CKD, after high loading doses and with nephrotoxic drugs. Hearing tests with ototoxic or nephrotoxic co-medication. Blood counts periodically (SmPC 4.4). Kidney
  • Trough levels after loading and at least weekly
  • Kidney function, especially with high loading doses or nephrotoxic drugs
  • Hearing with ototoxic co-medication
  • Blood counts periodically
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityNot absorbed orally (oral use is for colitis only)
Half-lifeTerminal 100 to 170 hours
Half-life in kidney failure (ESKD) kidneyProlonged; clearance tracks creatinine clearance (not quantified)
Volume of distribution0.7 to 1.4 L/kg (steady state)
Protein binding87.6% to 90.8% (albumin)
Metabolism (CYP, transporters)Minimal (2% to 3% hydroxylated)
Renal excretion kidneyAbout 80% unchanged in urine over 16 days
Dialyzability kidneyNot removed by hemodialysis; slowly by peritoneal dialysis
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Swedish Medical Products Agency. Targocid powder for solution for injection/infusion SmPC (English) [MPA (Sweden) product information, December 11, 2025; no US FDA label]. https://docetp.mpa.se/LMF/Targocid%20powder%20for%20solution%20for%20injection%20or%20infusion%20ENG%20SmPC_09001bee84dd93a5.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Sanofi. (2025). Targocid 200 mg and 400 mg powder for solution for injection/infusion or oral solution (teicoplanin) [Summary of product characteristics, English; revised December 11, 2025]. Swedish Medical Products Agency (Läkemedelsverket). https://docetp.mpa.se/LMF/Targocid%20powder%20for%20solution%20for%20injection%20or%20infusion%20ENG%20SmPC_09001bee84dd93a5.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .